Quantum BioPharma Ltd
QNTM8.890USD
+0.070+0.79%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
33.93MMarket Cap
LossP/E TTM
More Details of Quantum BioPharma Ltd Company
Quantum BioPharma Ltd. is a Canada-based biopharmaceutical company. The Company is engaged in building a portfolio of assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., it is focused on the research and development of its lead compound, Lucid-MS, which is a patented new chemical entity to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis. The Company has also licensed unbuzzd, a formulation of natural ingredients, vitamins, and minerals to help with liver and brain function for the purposes of quickly relieving individuals from the effects of alcohol consumption. It maintains a portfolio of strategic investments through its wholly owned subsidiary, FSD Strategic Investments Inc., which represents loans secured by residential or commercial property.
Quantum BioPharma Ltd Info
Ticker SymbolQNTM
Company nameQuantum Biopharma Ltd
IPO dateMay 29, 2018
CEOKotra (Lakshmi P)
Number of employees- -
Security typeOrdinary Share
Fiscal year-endMay 29
Address55 University Ave. , Suite 1003
CityTORONTO
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryCanada
Postal codeM5J 2H7
Phone14168548884
Websitehttps://www.quantumbiopharma.com/
Ticker SymbolQNTM
IPO dateMay 29, 2018
CEOKotra (Lakshmi P)
Company Executives of Quantum BioPharma Ltd
Name
Name/Position
Position
Shareholding
Change
Mr. Zeeshan Saeed
Mr. Zeeshan Saeed
Executive Co-Chairman of the Board, President, Chief Executive Officer
Executive Co-Chairman of the Board, President, Chief Executive Officer
118.41K
+0.25%
Mr. Donal Carroll, CPA
Mr. Donal Carroll, CPA
Chief Financial Officer
Chief Financial Officer
90.41K
+9.30%
Mr. Anthony Durkacz
Mr. Anthony Durkacz
Co-Executive Chairman of the Board
Co-Executive Chairman of the Board
29.11K
-72.73%
Mr. Adnan Bashir
Mr. Adnan Bashir
Independent Director
Independent Director
--
--
Mr. Joseph L. Romano
Mr. Joseph L. Romano
Director
Director
--
--
Mr. Lawrence (Larry) Latowsky
Mr. Lawrence (Larry) Latowsky
Independent Director
Independent Director
--
--
Mr. Kevin Cassidy
Mr. Kevin Cassidy
Vice President - Quality of Lucid
Vice President - Quality of Lucid
--
--
Dr. Andrzej Chruscinski, M.D., Ph.D.
Dr. Andrzej Chruscinski, M.D., Ph.D.
Vice President - Clinical and Scientific Affairs
Vice President - Clinical and Scientific Affairs
--
-100.00%
Dr. Lakshmi P. Kotra, Ph.D.
Dr. Lakshmi P. Kotra, Ph.D.
Chief Executive Officer of Lucid, Director, President of FSD Biosciences and CEO of FSD Australia
Chief Executive Officer of Lucid, Director, President of FSD Biosciences and CEO of FSD Australia
--
--
Dr. Eric Hoskins, M.D.
Dr. Eric Hoskins, M.D.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Zeeshan Saeed
Mr. Zeeshan Saeed
Executive Co-Chairman of the Board, President, Chief Executive Officer
Executive Co-Chairman of the Board, President, Chief Executive Officer
118.41K
+0.25%
Mr. Donal Carroll, CPA
Mr. Donal Carroll, CPA
Chief Financial Officer
Chief Financial Officer
90.41K
+9.30%
Mr. Anthony Durkacz
Mr. Anthony Durkacz
Co-Executive Chairman of the Board
Co-Executive Chairman of the Board
29.11K
-72.73%
Mr. Adnan Bashir
Mr. Adnan Bashir
Independent Director
Independent Director
--
--
Mr. Joseph L. Romano
Mr. Joseph L. Romano
Director
Director
--
--
Mr. Lawrence (Larry) Latowsky
Mr. Lawrence (Larry) Latowsky
Independent Director
Independent Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Tue, Dec 2
Updated: Tue, Dec 2
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Malone Wealth Ventures LLC
27.43%
Saeed (Zeeshan)
3.10%
Carroll (Donal)
2.37%
Lynch (Terrence)
1.35%
AdvisorShares Investments, LLC
0.98%
Other
64.77%
Shareholders
Shareholders
Proportion
Malone Wealth Ventures LLC
27.43%
Saeed (Zeeshan)
3.10%
Carroll (Donal)
2.37%
Lynch (Terrence)
1.35%
AdvisorShares Investments, LLC
0.98%
Other
64.77%
Shareholder Types
Shareholders
Proportion
Investment Advisor
29.12%
Individual Investor
8.54%
Investment Advisor/Hedge Fund
1.36%
Corporation
0.37%
Research Firm
0.09%
Other
60.52%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
40
1.17M
30.70%
+254.90K
2025Q2
50
1.04M
35.99%
+612.85K
2025Q1
50
413.46K
17.05%
-229.58K
2024Q4
44
604.87K
28.35%
+138.76K
2024Q3
45
583.17K
30.09%
+414.87K
2024Q2
43
126.91K
14.87%
-21.03K
2024Q1
47
105.72K
14.06%
-57.49K
2023Q4
49
159.35K
26.32%
+20.22K
2023Q3
52
164.58K
27.23%
+48.13K
2023Q2
52
164.21K
27.10%
+38.85K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Malone Wealth Ventures LLC
1.05M
27.43%
+217.43K
+26.20%
Sep 06, 2025
Saeed (Zeeshan)
118.41K
3.1%
+300.00
+0.25%
Aug 14, 2025
Carroll (Donal)
90.41K
2.37%
+7.69K
+9.30%
Apr 03, 2025
Lynch (Terrence)
51.42K
1.35%
+51.42K
--
Aug 14, 2025
AdvisorShares Investments, LLC
36.99K
0.97%
-12.00K
-24.49%
Jun 30, 2025
Kotra (Lakshmi)
29.57K
0.77%
--
--
Aug 14, 2025
Durkacz (Anthony)
106.76K
2.8%
--
--
Aug 14, 2025
UBS Financial Services, Inc.
45.88K
1.2%
+44.27K
+2742.81%
Jun 30, 2025
Saeed (Rehan)
6.79K
0.18%
-2.15K
-24.09%
Dec 31, 2024
View more
Related ETFs
Updated: Tue, Dec 2
Updated: Tue, Dec 2
Name
Proportion
AdvisorShares Psychedelics ETF
6.05%
AdvisorShares Psychedelics ETF
Proportion6.05%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Aug 12, 2024
Merger
65→1
Aug 12, 2024
Merger
65→1
Aug 12, 2024
Merger
65→1
Aug 12, 2024
Merger
65→1
Date
Type
Ratio
Aug 12, 2024
Merger
65→1
Aug 12, 2024
Merger
65→1
Aug 12, 2024
Merger
65→1
Aug 12, 2024
Merger
65→1
FAQs
Who are the top five shareholders of Quantum BioPharma Ltd?
The top five shareholders of Quantum BioPharma Ltd are:
Malone Wealth Ventures LLC holds 1.05M shares, accounting for 27.43% of the total shares.
Saeed (Zeeshan) holds 118.41K shares, accounting for 3.10% of the total shares.
Carroll (Donal) holds 90.41K shares, accounting for 2.37% of the total shares.
Lynch (Terrence) holds 51.42K shares, accounting for 1.35% of the total shares.
AdvisorShares Investments, LLC holds 36.99K shares, accounting for 0.97% of the total shares.
Malone Wealth Ventures LLC holds 1.05M shares, accounting for 27.43% of the total shares.
Saeed (Zeeshan) holds 118.41K shares, accounting for 3.10% of the total shares.
Carroll (Donal) holds 90.41K shares, accounting for 2.37% of the total shares.
Lynch (Terrence) holds 51.42K shares, accounting for 1.35% of the total shares.
AdvisorShares Investments, LLC holds 36.99K shares, accounting for 0.97% of the total shares.
What are the top three shareholder types of Quantum BioPharma Ltd?
The top three shareholder types of Quantum BioPharma Ltd are:
Malone Wealth Ventures LLC
Saeed (Zeeshan)
Carroll (Donal)
Malone Wealth Ventures LLC
Saeed (Zeeshan)
Carroll (Donal)
How many institutions hold shares of Quantum BioPharma Ltd (QNTM)?
As of 2025Q3, 40 institutions hold shares of Quantum BioPharma Ltd, with a combined market value of approximately 1.17M, accounting for 30.70% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -5.29%.
What is the biggest source of revenue for Quantum BioPharma Ltd?
In --, the -- business generated the highest revenue for Quantum BioPharma Ltd, amounting to -- and accounting for --% of total revenue.
